Table 1.

The new combinatorial CpG ODN-based cancer immunotherapies in clinical trials

Product	Target	Institution	Development phase
IMO-2125 CpG-3’-3’ fusion	TLR9/CTLA-4	Idera Pharmaceutical	Phase 1/2 (metastatic melanoma): in combination with ipilimumab
SD-101 CpG-C	TLR9/PD-1	Dynavax	Phase 1/2 (metastatic melanoma): in combination with pembrolizumab
MGN1703 double loop CpG	TLR9/CTLA-4	Mologene AG	Phase 1 (advanced solid tumors): in combination with ipilimumab
CMP-001 CpG-A/VLP	TLR9/PD-1	Checkmate Pharmaceuticals	Phase 1/2 (advanced melanoma): in combination with pembrolizumab
CSI-2 CpG-B conjugate	TLR9/STAT3	City of Hope	Phase 1 planned for 2019 (Non-Hodgkin’s B cell lymphoma)